Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer’s Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM)
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Behavioral and psychological symptoms of dementia are common in Alzheimer's disease (AD) and associated with a more rapid decline in cognitive function. Psychotropic substances are frequently used in AD, but we lack conclusive evidence of their efficacy in this setting. SSRI and trazodone were reported to have positive effects on cognition. Based on the prospective registry of dementia in Austria (PRODEM), we investigated the effects of psychotropic substances on cognition, behavioral symptoms, and caregiver burden (CB) in patients with AD, followed up prospectively over a 12-month period. We used the Mini-Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), and the Zarit caregiver burden interview. The study cohort consisted of 309 patients. Patients taking no psychotropic drugs (NO) or those undergoing consistent monotherapy with a psychotropic drug for 12 months were analyzed further (NO 101 patients, SSRI 22, trazodone 8, atypical neuroleptics or benzodiazepines (ANL/BZD) 18). Additionally, the subgroup of patients who started taking any of the substances during the study period were analyzed further to determine the effects before versus six months after the start of medication. MMSE, NPI, and CB at baseline and during follow-up did not differ between the groups. MMSE and CB declined over 12 months in the overall group (MMSE: 21.2±4 versus 19.7±5, p = 0.001 and CB 20.3±12 versus 24.7±14.2, p = 0.007), but no statistically significant changes were registered within groups over 12 months. When trazodone was started, only NPI improved significantly after 6 months (33.4±18 versus 18.9±22.7, p < 0.01). ANL/BZD or SSRI, when started, did not alter MMSE, NPI, or CB. SSRI had no beneficial effect on cognition. We conclude that trazodone might be helpful in the treatment of behavioral symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The subjects in this study had mild to moderate Alzheimer’s dementia and showed no change in AD-Cog scores after treatment with BZD [74].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [74]
In the citing paper
“Researchers in this study also cautioned, however, that these drugs are known to cause delirium, falls, and other adverse events in the elderly, so when possible, prescribers should either abstain from prescribing BZD to elderly patients or deprescribe them when possible [74].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [74]
In the citing paper
“One study showed that administration of BZD in patients with Alzheimer’s disease do not lead to further cognitive decline after 18 months of taking the drug [74].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [74]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Zhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916
Peters, M. E., Schwartz, S., Han, D., Rabins, P. V., Steinberg, M., Tschanz, J. T., & Lyketsos, C. G. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14040480 · Cited by 400 · cited 1×
“Behavioral and psychological symptoms are common in patients with Alzheimer’s disease (AD), contribute substantially to their morbidity, and may precede cognitive symptoms [1].”
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202
Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes
Weintraub, D., Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Porsteinsson, A. P., Schneider, L. S., Munro, C. A., Meinert, C. L., Lyketsos, C. G., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cc0333 · Cited by 183
Camargos, E. F., Louzada, L. L., Quintas, J. L., Naves, J. O. S., Louzada, F. M., & Nóbrega, O. T. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.174 · Cited by 170
Zahodne, L. B., Ornstein, K., Cosentino, S., Devanand, D. P., & Stern, Y. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.014 · Cited by 145
Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia
Nowrangi, M. A., Lyketsos, C. G., & Rosenberg, P. B. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0096-3 · Cited by 129
Research works printed but not linked: 1
- Bartels, 2018, Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression, Am J Psychiatry, 175, 232, 10.1176/appi.ajp.2017.17040404 · DOI · Paper page
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 66
Pekar, T., Bruckner, K., Pauschenwein-Frantsich, S., Gschaider, A., Oppliger, M., Willesberger, J., Ungersbäck, P., Wendzel, A., Kremer, A., Flak, W., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01758-y · Cited by 57
Cacabelos, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779700 · Cited by 52
Impact of psychotropic medications on cognition among older adults: a systematic review
Chandramouleeshwaran, S., Khan, W. U., Inglis, F., & Rajji, T. K. (2023) · International Psychogeriatrics · doi:10.1017/s1041610223000844 · Cited by 39
Metadata
- Authors
- Pirker-Kees, A., Dal-Bianco, P., & Schmidt, R.
- Affiliations
- Klinik Hietzing (AT)
- Department of Neurology, Medical University Vienna, Vienna, Austria
- Medical University of Graz (AT)
- Corresponding author
- Pirker-Kees, Agnes
- Venue
- Journal of Alzheimer s Disease
- Publisher
- SAGE Publications
- Published
- 2019-09-17
- Volume
- 71
- Issue
- 2
- Pages
- 623-630
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2967313104
- Cited by
- 17
- References
- 25
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 4
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- Alzheimer's disease, psychotropic drugs
- MeSH terms
- Adaptation, Psychological, Aged, Aged, 80 and over, Alzheimer Disease, Austria, Mental Disorders, Cognition, Dementia, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Prospective Studies, Psychotropic Drugs, Registries, Time Factors, Cohort Studies, Treatment Outcome, Caregivers, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.